Long-term Survival after Surgical Treatment of Metachronous Bilateral Adrenal Metastases of Non-small Cell Lung Carcinoma

Taira, Naohiro; Kawabata, Tsutomu; Ichi, Takaharu; Kushi, Kazuaki; Yohena, Tomofumi; Kawasaki, Hidenori; Ishikawa, Kiyoshi

doi:10.12659/ajcr.891027

Cited by 7 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer, especially NSCLC, is the most common cause of cancer death in the world, and its incidence is steadily increasing [ 1 ]. NSCLC always spreads to further sites through hematologic or lymphatic means like adrenal glands and most lung cancer patients with adrenal glands are incurable [ 35 ]. The poor prognosis of lung cancer is principally due to diagnosis made at advanced clinical stages.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer

et al. 2015

View full text Add to dashboard Cite

BackgroundRecent reports have suggested that miR-30a plays a tumor-suppressive role in various cancers. However, miR-30a has not been completely studied in non-small lung cancer (NSCLC). Thus, the aim of the present study was to clarify the association between the expression of miR-30a and the clinicopathological features in NSCLC patients.Material/MethodsTotal RNA of miR-30a was extracted from 125 pairs of NSCLC patients (male 75, female 50) and their matching normal tissues. The miR-30a level was detected by using quantitative real-time polymerase chain reaction (qRT-PCR). Simultaneously, the 2−ΔCq method was used to calculate the correlation between miR-30a expression and the clinicopathological parameters and prognosis of NSCLC patients.ResultsMiR-30a expression was significantly down-regulated in NSCLC tissues (4.0696±2.4178) compared to their non-tumor lung tissues (7.4530±3.0561, P<0.001). Level of miR-30a was negatively correlated to tumor size (r=−0.197, P=0.028), lymphatic metastasis (r=−0.312, P<0.001), clinical TNM stage (r=−0.299, P=0.001), pathological grading (I/II vs. III, r=−0.224, P=0.001), and histological classification (r=−0.299, P=0.001). Survival time was 3.23±2.18 months in the low miR-30a expression group, remarkably shorter than that of the high expression group (20.72±11.63 months, P<0.001).ConclusionsMiR-30a may be regarded as a tumor suppressor in NSCLC, and it could become a prognostic marker and potential therapeutic target for NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A large body of evidence [ 25 – 28 ] suggests that CD44 gene participates in the regulation of tumor metastasis and that overexpression of CD44 is particularly observed in metastatic tumors, especially in those cancers that have a high propensity for the development of bone metastases [ 37 , 43 , 44 ]. Moreover, the overexpression of CD44 in the primary tumor is reportedly associated with early metastasis and poor prognosis in human cancers [ 26 , 37 , 43 – 45 ].…”

Section: Discussionmentioning

confidence: 99%

Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis

Liu

Qing

et al. 2015

Med Sci Monit

View full text Add to dashboard Cite

BackgroundPrevious studies have reported CD44 expression influenced the development and progression of tumors. The aim of this study was to investigate whether single-nucleotide polymorphisms (SNPs) of the CD44 gene are associated with survival of non-small cell lung cancer (NSCLC) and occurrence rate of bone metastasis.Material/MethodsA total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher’s exact test, Kaplan-Meier method, and log-rank test.ResultsCD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20–0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50–4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34–0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31–0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05–2.21, P=0.027).ConclusionsCD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.

show abstract

“…However, the success of aggressive resection for solitary cerebral metastasis makes surgeons reconsider this issue. Case reports and studies have suggested an increased survival for patients who undergo resection of solitary adrenal metastasis from NSCLC 5,10–13. Vazquez et al reported their 21 patients who underwent resection of solitary adrenal metastasis from NSCLC had a median survival of 3.5 years and 1-year survival of 91% 7.…”

Section: Discussionmentioning

confidence: 99%

Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer

Huang

Kong

Chen

et al. 2017

TCRM

View full text Add to dashboard Cite

Background and purposeSeveral case reports and studies have suggested that there is an increased survival rate for patients who undergo resection of solitary adrenal metastasis from non-small cell lung cancer (NSCLC). This study aimed to investigate whether NSCLC patients with solitary adrenal metastasis could gain a higher survival rate after adrenalectomy (ADX) when compared with those patients undergoing nonsurgical treatment, and to investigate the potential prognostic factors.Patients and methodsA total of 1,302 NSCLC inpatients’ data from 2001 to 2015 were retrospectively reviewed to identify those with solitary adrenal metastasis. Overall survival for those who underwent both primary resection and ADX was compared to those patients with conservative treatment using the log-rank test. Potential prognostic variables were evaluated with univariate and multivariate analyses including clinical, therapeutic, pathologic, primary and metastatic data.ResultsA total of 22 NSCLC patients with solitary adrenal metastasis were identified, with an overall median survival of 11 months (95% confidence interval: 9.4–12.6 months) and a 1-year survival rate of 51.4% (95% confidence interval: 29.6%–73.2%). All of the patients had died by 30 months. There was no significant survival difference between patients who underwent primary and metastasis resection (n=10) and those treated conservatively (n=12), (P=0.209). Univariate analysis identified Eastern Cooperative Oncology Group performance status (ECOG PS) as the significant predictor of survival (P=0.024). Age (<65 vs ≥65 years), sex, pathologic type, mediastinal lymph node stage (N2 vs N0/N1), primary tumor size (<5 vs ≥5 cm), primary location (central vs peripheral), metastatic tumor size (<5 vs ≥5 cm), metastasis laterality, synchronous metastasis, and metastatic field radiotherapy were not identified as potential prognostic factors in relation to survival rate. In multivariate analysis, a stepwise selection procedure allowed both ECOG PS (P=0.007, relative risk =3.57) and pathologic type (P=0.069) to enter the Cox’s hazard function.ConclusionPrimary and metastatic radical resection may not prolong the survival of NSCLC patients with solitary adrenal metastasis. ECOG PS and pathologic type might be the prognostic factors for these patients.

show abstract

Long-term Survival after Surgical Treatment of Metachronous Bilateral Adrenal Metastases of Non-small Cell Lung Carcinoma

Cited by 7 publications

References 8 publications

Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer

Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer

Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis

Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer

Contact Info

Product

Resources

About